Published in J Exp Med on July 01, 1993
Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol (1996) 10.26
The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages. Proc Natl Acad Sci U S A (2000) 4.82
ideR, An essential gene in mycobacterium tuberculosis: role of IdeR in iron-dependent gene expression, iron metabolism, and oxidative stress response. Infect Immun (2002) 4.54
The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc Natl Acad Sci U S A (1998) 3.47
Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A (2000) 3.07
Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Infect Immun (1994) 2.61
Outer surface protein C (OspC), but not P39, is a protective immunogen against a tick-transmitted Borrelia burgdorferi challenge: evidence for a conformational protective epitope in OspC. Infect Immun (1996) 2.49
Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection. Infect Immun (1998) 2.29
Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect Immun (1996) 1.98
Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice. Antimicrob Agents Chemother (1996) 1.88
Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab. Proc Natl Acad Sci U S A (1997) 1.78
Bacterial glycoproteins: a link between glycosylation and proteolytic cleavage of a 19 kDa antigen from Mycobacterium tuberculosis. EMBO J (1996) 1.74
Variability of a bacterial surface protein and disease expression in a possible mouse model of systemic Lyme borreliosis. J Exp Med (1994) 1.73
Early and late antibody responses to full-length and truncated constructs of outer surface protein A of Borrelia burgdorferi in Lyme disease. Infect Immun (1995) 1.68
Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci U S A (1998) 1.63
Mycobacterial polyketide-associated proteins are acyltransferases: proof of principle with Mycobacterium tuberculosis PapA5. Proc Natl Acad Sci U S A (2004) 1.60
Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A. J Exp Med (1994) 1.55
Analysis of the Mycobacterium tuberculosis 85A antigen promoter region. J Bacteriol (1995) 1.48
Rapid assay for mycobacterial growth and antibiotic susceptibility using gel microdrop encapsulation. J Clin Microbiol (1995) 1.48
The T helper cell response in Lyme arthritis: differential recognition of Borrelia burgdorferi outer surface protein A in patients with treatment-resistant or treatment-responsive Lyme arthritis. J Exp Med (1994) 1.41
Development of destructive arthritis in vaccinated hamsters challenged with Borrelia burgdorferi. Infect Immun (1994) 1.30
Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env. J Virol (2006) 1.22
Identification of mycobacterium tuberculosis DNA sequences encoding exported proteins by using phoA gene fusions. J Bacteriol (1995) 1.22
Identification and characterization of SirA, an iron-regulated protein from Staphylococcus aureus. J Bacteriol (1999) 1.19
Plasmidic versus insertional cloning of heterologous genes in Mycobacterium bovis BCG: impact on in vivo antigen persistence and immune responses. Infect Immun (2002) 1.19
Surface display of a functional single-chain Fv antibody on staphylococci. J Bacteriol (1996) 1.19
Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi. Infect Immun (1995) 1.18
Nitrile-inducible gene expression in mycobacteria. Tuberculosis (Edinb) (2008) 1.18
Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice. Infect Immun (2000) 1.17
Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun (1997) 1.06
Surface display of the cholera toxin B subunit on Staphylococcus xylosus and Staphylococcus carnosus. Appl Environ Microbiol (1997) 1.04
Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J Virol (2007) 1.04
Virulence, immunogenicity, and protective efficacy of two recombinant Mycobacterium bovis bacillus Calmette-Guérin strains expressing the antigen ESAT-6 from Mycobacterium tuberculosis. Infect Immun (2003) 1.01
Selection of variant Borrelia burgdorferi isolates from mice immunized with outer surface protein A or B. Infect Immun (1995) 1.00
IFN-gamma induces the erosion of preexisting CD8 T cell memory during infection with a heterologous intracellular bacterium. J Immunol (2008) 1.00
Cross-species surface display of functional spirochetal lipoproteins by recombinant Borrelia burgdorferi. Infect Immun (2004) 0.99
Generation of mucosal anti-human immunodeficiency virus type 1 T-cell responses by recombinant Mycobacterium smegmatis. Clin Vaccine Immunol (2006) 0.99
Secretion of human interleukin 2 by recombinant Mycobacterium bovis BCG. Infect Immun (1995) 0.96
Recombinant Mycobacterium bovis BCG as an HIV vaccine vector. Curr HIV Res (2010) 0.90
Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells. PLoS One (2012) 0.90
Mycobacterium bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen. Infect Immun (1994) 0.90
Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge. Infect Immun (2004) 0.89
Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice. Infect Immun (2010) 0.89
Evaluation of a recombinant BCG expressing antigen Ag85B and PPE protein Rv3425 from DNA segment RD11 of Mycobacterium tuberculosis in C57BL/6 mice. Med Microbiol Immunol (2008) 0.89
Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes. Clin Dev Immunol (2011) 0.86
The next wave of recombinant and synthetic anticancer vaccines. Semin Cancer Biol (1995) 0.85
Immunogenicity and protection studies with recombinant mycobacteria and vaccinia vectors coexpressing the 18-kilodalton protein of Mycobacterium leprae. Infect Immun (1996) 0.85
Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer. Clin Dev Immunol (2011) 0.84
Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG. PLoS One (2012) 0.84
The tuberculosis vaccine candidate Bacillus Calmette-Guérin ΔureC::hly coexpressing human interleukin-7 or -18 enhances antigen-specific T cell responses in mice. PLoS One (2013) 0.83
P55, an immunogenic but nonprotective 55-kilodalton Borrelia burgdorferi protein in murine Lyme disease. Infect Immun (1996) 0.83
Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control. Tuberc Res Treat (2011) 0.83
An epitope delivery system for use with recombinant mycobacteria. Infect Immun (1998) 0.83
Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant Mycobacterium bovis BCG expressing CRM(197), a mutant diphtheria toxin. Infect Immun (2001) 0.82
Lyme borreliosis in transgenic mice tolerant to Borrelia burgdorferi OspA or B. J Clin Invest (1995) 0.82
Inhibition of the production of anti-OspA borreliacidal antibody with T cells from hamsters vaccinated against Borrelia burgdorferi. Infect Immun (1998) 0.81
Recombinant Staphylococcus strains as live vectors for the induction of neutralizing anti-diphtheria toxin antisera. Infect Immun (1999) 0.81
Recombinant Mycobacterium bovis BCG expressing the chimeric protein of antigen 85B and ESAT-6 enhances the Th1 cell-mediated response. Clin Vaccine Immunol (2009) 0.80
Analysis of recombinant mycobacteria as T helper type 1 vaccines in an allergy challenge model. Immunology (2001) 0.79
Staphylococcal surface display of immunoglobulin A (IgA)- and IgE-specific in vitro-selected binding proteins (affibodies) based on Staphylococcus aureus protein A. Appl Environ Microbiol (1999) 0.78
Genetic control of antibody responses induced by recombinant Mycobacterium bovis BCG expressing a foreign antigen. Infect Immun (1997) 0.77
Preclinical Development of BCG.HIVA(2auxo.int), Harboring an Integrative Expression Vector, for a HIV-TB Pediatric vaccine. Enhancement of Stability and Specific HIV-1 T-cell Immunity. Hum Vaccin Immunother (2017) 0.76
Enhanced priming of adaptive immunity by Mycobacterium smegmatis mutants with high-level protein secretion. Clin Vaccine Immunol (2012) 0.76
Comparative protective effects of recombinant DNA and Mycobacterium bovis bacille Calmette-Guérin vaccines against M. avium infection. Clin Exp Immunol (2001) 0.75
Recombinant Mycobacterium smegmatis with a pMyong2 vector expressing Human Immunodeficiency Virus Type I Gag can induce enhanced virus-specific immune responses. Sci Rep (2017) 0.75
The use of directed evolution to create a stable and immunogenic recombinant BCG expressing a modified HIV-1 Gag antigen. PLoS One (2014) 0.75
Phase separation of integral membrane proteins in Triton X-114 solution. J Biol Chem (1981) 26.33
New use of BCG for recombinant vaccines. Nature (1991) 14.40
Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science (1990) 7.33
Molecular analysis of linear plasmid-encoded major surface proteins, OspA and OspB, of the Lyme disease spirochaete Borrelia burgdorferi. Mol Microbiol (1989) 6.51
Lipoproteins in bacteria. J Bioenerg Biomembr (1990) 5.96
In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature (1989) 5.08
Antigenic variability of Borrelia burgdorferi. Ann N Y Acad Sci (1988) 5.02
Lysogeny and transformation in mycobacteria: stable expression of foreign genes. Proc Natl Acad Sci U S A (1988) 4.90
Immunogenic integral membrane proteins of Borrelia burgdorferi are lipoproteins. Infect Immun (1990) 4.10
Cloning and expression of the Mycobacterium bovis BCG gene for extracellular alpha antigen. J Bacteriol (1988) 3.97
Genetic control of natural resistance to Mycobacterium bovis (BCG) in mice. J Immunol (1981) 3.95
Introduction of foreign DNA into mycobacteria using a shuttle phasmid. Nature (1987) 3.83
Cloning, sequence determination, and expression of a 32-kilodalton-protein gene of Mycobacterium tuberculosis. Infect Immun (1989) 3.64
Recombinant outer surface protein a from Borrelia burgdorferi induces antibodies protective against spirochetal infection in mice. J Infect Dis (1991) 3.58
The lipoprotein of the outer membrane of Escherichia coli: a B-lymphocyte mitogen. J Exp Med (1975) 3.55
Structure and mapping of antigenic domains of protein antigen b, a 38,000-molecular-weight protein of Mycobacterium tuberculosis. Infect Immun (1989) 3.43
A single recombinant plasmid expressing two major outer surface proteins of the Lyme disease spirochete. Science (1985) 3.42
Identification and localization of integral membrane proteins of virulent Treponema pallidum subsp. pallidum by phase partitioning with the nonionic detergent triton X-114. Infect Immun (1988) 3.42
Organization of genes encoding two outer membrane proteins of the Lyme disease agent Borrelia burgdorferi within a single transcriptional unit. Infect Immun (1986) 3.39
Roles of OspA, OspB, and flagellin in protective immunity to Lyme borreliosis in laboratory mice. Infect Immun (1992) 3.04
Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. Proc Natl Acad Sci U S A (1992) 2.99
The urinary bladder, a consistent source of Borrelia burgdorferi in experimentally infected white-footed mice (Peromyscus leucopus). J Clin Microbiol (1988) 2.85
Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature (1991) 2.83
Infectivity of Borrelia burgdorferi relative to route of inoculation and genotype in laboratory mice. J Infect Dis (1991) 2.37
In vitro inhibition of Borrelia burgdorferi growth by antibodies. J Infect Dis (1993) 2.31
Outer surface protein A (OspA) from the Lyme disease spirochete, Borrelia burgdorferi: high level expression and purification of a soluble recombinant form of OspA. Protein Expr Purif (1990) 2.23
Human T cell clones recognize two abundant Mycobacterium tuberculosis protein antigens expressed in Escherichia coli. J Immunol (1987) 2.19
Lipoprotein antigens of Mycobacterium tuberculosis. Res Microbiol (1991) 2.15
Major integral membrane protein immunogens of Treponema pallidum are proteolipids. Infect Immun (1989) 2.15
Cloning and expression of the gene for the cross-reactive alpha antigen of Mycobacterium kansasii. Infect Immun (1990) 2.06
Evidence for three separate genes encoding the proteins of the mycobacterial antigen 85 complex. Infect Immun (1990) 2.06
Biologic activities of antibody to a peptidoglycan-associated lipoprotein of Haemophilus influenzae against multiple clinical isolates of H. influenzae type b. Infect Immun (1987) 1.82
Nucleotide sequence of the 19 kDa antigen gene from Mycobacterium tuberculosis. Nucleic Acids Res (1989) 1.70
Clinical value of the measurement of Mycobacterium tuberculosis specific antibody in pulmonary tuberculosis. Thorax (1992) 1.62
Probing the topology of a bacterial membrane protein by genetic insertion of a foreign epitope; expression at the cell surface. EMBO J (1986) 1.50
Humoral and cell-mediated immunity in mice to a 17-kilodalton lipoprotein of Francisella tularensis expressed by Salmonella typhimurium. Infect Immun (1992) 1.46
Development of BCG as a recombinant vaccine vehicle. Curr Top Microbiol Immunol (1990) 1.19
Establishment of a foreign antigen secretion system in mycobacteria. Infect Immun (1990) 1.18
The major anaerobically induced outer membrane protein of Neisseria gonorrhoeae, Pan 1, is a lipoprotein. Infect Immun (1992) 1.12
Molecular cloning, expression, and DNA sequence analysis of the gene that encodes the 16-kilodalton outer membrane lipoprotein of Serpulina hyodysenteriae. Infect Immun (1993) 1.08
Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli. Infect Immun (1990) 1.07
Lipopeptide derivatives of bacterial lipoprotein constitute potent immune adjuvants combined with or covalently coupled to antigen or hapten. Biol Chem Hoppe Seyler (1989) 1.04
Antibodies to a common outer envelope antigen of Treponema hyodysenteriae with antibacterial activity. J Gen Microbiol (1989) 1.01
K88 fimbriae as carriers of heterologous antigenic determinants. Microb Pathog (1990) 0.88
Expression of viral hemagglutinin on the surface of E. coli. Klin Wochenschr (1988) 0.86
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Lyme disease-a tick-borne spirochetosis? Science (1982) 27.50
The spirochetal etiology of Lyme disease. N Engl J Med (1983) 21.59
Isolation and cultivation of Lyme disease spirochetes. Yale J Biol Med (1985) 20.49
New use of BCG for recombinant vaccines. Nature (1991) 14.40
IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science (1997) 11.89
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science (1986) 11.74
Spirochetes isolated from the blood of two patients with Lyme disease. N Engl J Med (1983) 11.15
Lyme disease spirochetes and ixodid tick spirochetes share a common surface antigenic determinant defined by a monoclonal antibody. Infect Immun (1983) 9.60
Heterogeneity of major proteins in Lyme disease borreliae: a molecular analysis of North American and European isolates. J Infect Dis (1985) 7.69
A Borrelia-specific monoclonal antibody binds to a flagellar epitope. Infect Immun (1986) 6.80
Variation in a major surface protein of Lyme disease spirochetes. Infect Immun (1984) 6.68
Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med (1986) 6.52
Molecular analysis of linear plasmid-encoded major surface proteins, OspA and OspB, of the Lyme disease spirochaete Borrelia burgdorferi. Mol Microbiol (1989) 6.51
Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. Cell (1997) 6.36
A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci U S A (1991) 6.13
Biology of Borrelia species. Microbiol Rev (1986) 6.03
Linear plasmids of the bacterium Borrelia burgdorferi have covalently closed ends. Science (1987) 5.80
Variable major proteins of Borrellia hermsii. J Exp Med (1982) 5.62
Natural Distribution of the Ixodes dammini spirochete. Science (1983) 5.24
Antigenic variability of Borrelia burgdorferi. Ann N Y Acad Sci (1988) 5.02
Spirochetes in Ixodes dammini and mammals from Connecticut. Am J Trop Med Hyg (1983) 4.86
Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol (1992) 4.72
Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science (1997) 4.57
Low-passage-associated proteins of Borrelia burgdorferi B31: characterization and molecular cloning of OspD, a surface-exposed, plasmid-encoded lipoprotein. Infect Immun (1992) 4.42
Transposition of structural genes to an expression sequence on a linear plasmid causes antigenic variation in the bacterium Borrelia hermsii. Nature (1985) 4.41
Megabase-sized linear DNA in the bacterium Borrelia burgdorferi, the Lyme disease agent. Proc Natl Acad Sci U S A (1989) 4.38
Chlamydia trachomatis has penicillin-binding proteins but not detectable muramic acid. J Bacteriol (1982) 4.33
Antibodies of patients with Lyme disease to components of the Ixodes dammini spirochete. J Clin Invest (1983) 4.08
Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis (1997) 3.88
Antigenic variation is associated with DNA rearrangements in a relapsing fever Borrelia. Cell (1985) 3.78
Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature (1990) 3.50
The cryptic ospC gene of Borrelia burgdorferi B31 is located on a circular plasmid. Infect Immun (1993) 3.50
Differentiation of Mycobacterium tuberculosis isolates by spoligotyping and IS6110 restriction fragment length polymorphism. J Clin Microbiol (1997) 3.46
A single recombinant plasmid expressing two major outer surface proteins of the Lyme disease spirochete. Science (1985) 3.42
Organization of genes encoding two outer membrane proteins of the Lyme disease agent Borrelia burgdorferi within a single transcriptional unit. Infect Immun (1986) 3.39
B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice. J Exp Med (1996) 3.35
Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol (1994) 3.33
Antibody-resistant mutants of Borrelia burgdorferi: in vitro selection and characterization. J Exp Med (1992) 3.30
Evolution of human influenza A viruses in nature: recombination contributes to genetic variation of H1N1 strains. Proc Natl Acad Sci U S A (1979) 3.13
Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet (1987) 2.98
Immunochemical characterization of a protein associated with Mycobacterium leprae cell wall. Infect Immun (1985) 2.88
Evolution of influenza A and B viruses: conservation of structural features in the hemagglutinin genes. Proc Natl Acad Sci U S A (1982) 2.86
Erythema chronicum migrans--a tickborne spirochetosis. Acta Trop (1983) 2.85
Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J Virol (1987) 2.84
CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Proc Natl Acad Sci U S A (1999) 2.81
Specificity of antibodies to immunodominant mycobacterial antigens in pulmonary tuberculosis. J Clin Microbiol (1988) 2.79
Clonal polymorphisms of outer membrane protein OspB of Borrelia burgdorferi. Infect Immun (1989) 2.76
Variation of influenza A, B, and C viruses. Science (1982) 2.75
DNA characterization of the spirochete that causes Lyme disease. J Clin Microbiol (1984) 2.71
Autoimmunity, microbial immunity and the immunological homunculus. Immunol Today (1991) 2.71
A stationary-phase stress-response sigma factor from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (1996) 2.70
IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex. Mol Cell Biol (1999) 2.68
Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun (2001) 2.68
Heterogeneity of outer membrane proteins in Borrelia burgdorferi: comparison of osp operons of three isolates of different geographic origins. Infect Immun (1992) 2.67
The Rapid Syndrome Validation Project (RSVP). Proc AMIA Symp (2001) 2.67
Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect Immun (1999) 2.65
Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J Exp Med (1996) 2.58
Transformation of mycobacterial species using hygromycin resistance as selectable marker. Microbiology (1994) 2.55
Cloning of 18S and 25S rDNAs from the pathogenic fungus Cryptococcus neoformans. J Bacteriol (1989) 2.55
The western black-legged tick, Ixodes pacificus: a vector of Borrelia burgdorferi. Am J Trop Med Hyg (1985) 2.50
T lymphocytes respond to solid-phase antigen: a novel approach to the molecular analysis of cellular immunity. Immunology (1986) 2.45
Linear- and circular-plasmid copy numbers in Borrelia burgdorferi. J Bacteriol (1992) 2.45
Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine. Science (1985) 2.44
Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med (1990) 2.41
High- and low-infectivity phenotypes of clonal populations of in vitro-cultured Borrelia burgdorferi. Infect Immun (1995) 2.39
Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J Infect Dis (2000) 2.37
Monoclonal antibodies to a 28,000 mol. wt protein antigen of Mycobacterium leprae. Clin Exp Immunol (1985) 2.36
Genetic diversity of Borrelia burgdorferi in lyme disease patients as determined by culture versus direct PCR with clinical specimens. J Clin Microbiol (1999) 2.35
Polymorphisms of major surface proteins of Borrelia burgdorferi. Zentralbl Bakteriol Mikrobiol Hyg A (1986) 2.33
The 14,000-molecular-weight antigen of Mycobacterium tuberculosis is related to the alpha-crystallin family of low-molecular-weight heat shock proteins. J Bacteriol (1992) 2.33
Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology (1983) 2.32
In vitro inhibition of Borrelia burgdorferi growth by antibodies. J Infect Dis (1993) 2.31
Complete nucleotide sequence of the influenza A/PR/8/34 virus NS gene and comparison with the NS genes of the A/Udorn/72 and A/FPV/Rostock/34 strains. Nucleic Acids Res (1980) 2.25
Sporadic occurrence of zoonotic swine influenza virus infections. J Clin Microbiol (1984) 2.24
Outer surface protein A (OspA) from the Lyme disease spirochete, Borrelia burgdorferi: high level expression and purification of a soluble recombinant form of OspA. Protein Expr Purif (1990) 2.23
Stress proteins may provide a link between the immune response to infection and autoimmunity. Int Immunol (1989) 2.21
Generation and characterization of monoclonal antibodies to the phenolic glycolipid of Mycobacterium leprae. Infect Immun (1984) 2.20
Efficient expression of influenza virus NS1 nonstructural proteins in Escherichia coli. Proc Natl Acad Sci U S A (1983) 2.19
A serological test for leprosy with a glycolipid specific for Mycobacterium leprae. Science (1983) 2.18
Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells. J Virol (2000) 2.17
Linear plasmids of Borrelia burgdorferi have a telomeric structure and sequence similar to those of a eukaryotic virus. J Bacteriol (1991) 2.15
Absence of lipopolysaccharide in the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun (1987) 2.15
Neuroborreliosis during relapsing fever: review of the clinical manifestations, pathology, and treatment of infections in humans and experimental animals. Clin Infect Dis (1998) 2.15
NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Ann Intern Med (1991) 2.15
Variable major proteins of Borrelia hermsii. Epitope mapping and partial sequence analysis of CNBr peptides. J Exp Med (1985) 2.12
Enzyme-linked immunosorbent assays for Lyme disease: reactivity of subunits of Borrelia burgdorferi. J Infect Dis (1989) 2.12
Mapping of T cell epitopes using recombinant antigens and synthetic peptides. EMBO J (1987) 2.09
Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science (1988) 2.09
Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+CD8+DR+CD25- T cell population. J Immunol (1990) 2.05
An outbreak of giardiasis in a group of campers. Am J Trop Med Hyg (1976) 2.04
Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics (1992) 2.02
Biological activity of protein antigens isolated from Mycobacterium tuberculosis culture filtrate. Infect Immun (1988) 2.01
The relapsing fever agent Borrelia hermsii has multiple copies of its chromosome and linear plasmids. Genetics (1992) 2.00